Asian Dividend Stocks To Watch In April 2025
As global markets grapple with heightened trade tensions and economic uncertainty, the Asian stock market has not been immune to these challenges, experiencing volatility amid new tariff announcements and shifting investor sentiment. In such an environment, dividend stocks can offer a measure of stability and income potential, making them an attractive option for investors seeking resilience in their portfolios.
Name
Dividend Yield
Dividend Rating
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)
6.21%
★★★★★★
CAC Holdings (TSE:4725)
5.44%
★★★★★★
Tsubakimoto Chain (TSE:6371)
5.06%
★★★★★★
Intelligent Wave (TSE:4847)
4.57%
★★★★★★
Nissan Chemical (TSE:4021)
4.21%
★★★★★★
ENEOS Holdings (TSE:5020)
4.24%
★★★★★★
HUAYU Automotive Systems (SHSE:600741)
4.48%
★★★★★★
Yamato Kogyo (TSE:5444)
4.35%
★★★★★★
E J Holdings (TSE:2153)
5.47%
★★★★★★
Torigoe (TSE:2009)
5.67%
★★★★★★
Click here to see the full list of 1310 stocks from our Top Asian Dividend Stocks screener.
Here's a peek at a few of the choices from the screener.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Dong-E-E-Jiao Ltd. engages in the research, development, production, and sale of Ejiao along with Chinese patent medicines and health foods, with a market cap of CN¥39.16 billion.
Operations: Dong-E-E-Jiao Ltd. generates revenue primarily from the operation of Ejiao and its related products, amounting to CN¥5.92 billion.
Dividend Yield: 4.2%
Dong-E-E-Jiao Ltd. has shown notable earnings growth, with net income rising to CNY 1.56 billion in 2024 from CNY 1.15 billion the previous year, but its dividend sustainability remains a concern due to a high payout ratio of nearly 100%. Despite being among the top dividend payers in China with a yield of 4.17%, the company's dividends have been volatile and not well covered by earnings or cash flows, impacting reliability for income-focused investors.
Dive into the specifics of Dong-E-E-JiaoLtd here with our thorough dividend report.
Our expertly prepared valuation report Dong-E-E-JiaoLtd implies its share price may be lower than expected.
Simply Wall St Dividend Rating: ★★★★★☆
Overview: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of medical products, with a market cap of approximately CN¥55.12 billion.
Operations: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. generates revenue from its primary segments, with CN¥24.24 billion from Pharmaceuticals, CN¥0.88 billion from Printing and Packaging, and CN¥4.17 billion from the Medicines, Equipment Wholesale and Retail Industry Segment.
Dividend Yield: 3.1%
China Resources Sanjiu Medical & Pharmaceutical's dividend yield of 3.08% ranks it in the top 25% of Chinese dividend payers, supported by a cash payout ratio of 46.9%, indicating solid coverage by cash flows. However, its dividends have been volatile over the past decade, affecting reliability despite recent earnings growth to CNY 3.37 billion in 2024 from CNY 2.85 billion a year earlier and a reasonable earnings payout ratio of 50.2%.
Get an in-depth perspective on China Resources Sanjiu Medical & Pharmaceutical's performance by reading our dividend report here.
In light of our recent valuation report, it seems possible that China Resources Sanjiu Medical & Pharmaceutical is trading behind its estimated value.
Simply Wall St Dividend Rating: ★★★★★★
Overview: Ono Pharmaceutical Co., Ltd. and its subsidiaries engage in the production, purchase, and sale of pharmaceuticals and diagnostic reagents globally, with a market cap of ¥762.34 billion.
Operations: Ono Pharmaceutical Co., Ltd. generates revenue of ¥487.33 billion from its pharmaceutical business segment.
Dividend Yield: 4.9%
Ono Pharmaceutical offers a compelling dividend profile with a yield of 4.93%, placing it in the top quartile of Japanese dividend payers. Its dividends are well-supported by earnings and cash flows, with payout ratios of 50.8% and 49.6%, respectively, ensuring sustainability. Despite recent profit margin declines to 15.2% from last year's 25.6%, dividends have remained stable and reliable over the past decade, although earnings are projected to decrease by an average of 2.5% annually for the next three years.
Delve into the full analysis dividend report here for a deeper understanding of Ono Pharmaceutical.
Our valuation report unveils the possibility Ono Pharmaceutical's shares may be trading at a discount.
Access the full spectrum of 1310 Top Asian Dividend Stocks by clicking on this link.
Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SZSE:000423 SZSE:000999 and TSE:4528.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Should You Think About Buying NanoXplore Inc. (TSE:GRA) Now?
NanoXplore Inc. (TSE:GRA), might not be a large cap stock, but it received a lot of attention from a substantial price movement on the TSX over the last few months, increasing to CA$2.50 at one point, and dropping to the lows of CA$2.24. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether NanoXplore's current trading price of CA$2.38 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at NanoXplore's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. According to our valuation model, NanoXplore seems to be fairly priced at around 9.4% below our intrinsic value, which means if you buy NanoXplore today, you'd be paying a fair price for it. And if you believe that the stock is really worth CA$2.63, then there isn't much room for the share price grow beyond what it's currently trading. Furthermore, NanoXplore's low beta implies that the stock is less volatile than the wider market. See our latest analysis for NanoXplore Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. In the upcoming year, NanoXplore's earnings are expected to increase by 27%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. Are you a shareholder? GRA's optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value? Are you a potential investor? If you've been keeping an eye on GRA, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. Diving deeper into the forecasts for NanoXplore mentioned earlier will help you understand how analysts view the stock going forward. Luckily, you can check out what analysts are forecasting by clicking here. If you are no longer interested in NanoXplore, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Is Pason Systems Inc.'s (TSE:PSI) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Pason Systems' (TSE:PSI) stock is up by a considerable 10% over the past month. Since the market usually pay for a company's long-term fundamentals, we decided to study the company's key performance indicators to see if they could be influencing the market. In this article, we decided to focus on Pason Systems' ROE. Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. The formula for return on equity is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Pason Systems is: 14% = CA$70m ÷ CA$499m (Based on the trailing twelve months to March 2025). The 'return' is the income the business earned over the last year. One way to conceptualize this is that for each CA$1 of shareholders' capital it has, the company made CA$0.14 in profit. Check out our latest analysis for Pason Systems So far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes. To start with, Pason Systems' ROE looks acceptable. And on comparing with the industry, we found that the the average industry ROE is similar at 14%. This probably goes some way in explaining Pason Systems' significant 34% net income growth over the past five years amongst other factors. We believe that there might also be other aspects that are positively influencing the company's earnings growth. Such as - high earnings retention or an efficient management in place. As a next step, we compared Pason Systems' net income growth with the industry and were disappointed to see that the company's growth is lower than the industry average growth of 56% in the same period. Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Pason Systems fairly valued compared to other companies? These 3 valuation measures might help you decide. The three-year median payout ratio for Pason Systems is 34%, which is moderately low. The company is retaining the remaining 66%. So it seems that Pason Systems is reinvesting efficiently in a way that it sees impressive growth in its earnings (discussed above) and pays a dividend that's well covered. Moreover, Pason Systems is determined to keep sharing its profits with shareholders which we infer from its long history of paying a dividend for at least ten years. Overall, we are quite pleased with Pason Systems' performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a respectable growth in its earnings. That being so, a study of the latest analyst forecasts show that the company is expected to see a slowdown in its future earnings growth. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Roots First Quarter 2026 Earnings: CA$0.20 loss per share (vs CA$0.22 loss in 1Q 2025)
Revenue: CA$40.0m (up 6.7% from 1Q 2025). Net loss: CA$7.91m (loss narrowed by 11% from 1Q 2025). CA$0.20 loss per share (improved from CA$0.22 loss in 1Q 2025). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 2.0% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Specialty Retail industry in Canada. Performance of the Canadian Specialty Retail industry. The company's shares are up 9.2% from a week ago. What about risks? Every company has them, and we've spotted 1 warning sign for Roots you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
